Draupnir Bio ApS
CVR 38546880 · Private limited company (ApS) · Active · High risk
Draupnir Bio ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 4.5% over the next 12 months, which is 3.2 times the average for Danish companies. 9 annual reports have been published. CEO: Andrew Thomas Hotchkiss.
Bankruptcy risk for Draupnir Bio ApS
3.2 × the average (1.41%) · higher risk than 91% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 38546880
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (9 years)
- Address
- c/o Symbion Fuglebakken, Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 1.3m
- Auditor
- DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 9 |
| Missing annual report | No |
| Negative equity | – |
| Equity ratio | – |
| Current ratio | – |
| Moves (last 2 years) | 0 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Avg. employees | 9 | 8 |
Latest annual report: Reporting class B · auditor's statement: Auditor's report on audited financial statements · Deloitte Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 155 | ||
| 1 Jan 2024 – 31 Dec 2024 | 178 | ||
| 1 Jan 2023 – 31 Dec 2023 | 136 | ||
| 1 Jan 2022 – 31 Dec 2022 | 163 | ||
| 1 Jan 2021 – 31 Dec 2021 | 161 | ||
| 1 Jan 2020 – 31 Dec 2020 | 172 | ||
| 1 Jan 2019 – 31 Dec 2019 | 149 | ||
| 1 Jan 2018 – 31 Dec 2018 | 155 | ||
| 4 Apr 2017 – 31 Dec 2017 | 87 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Andrew Thomas Hotchkiss | Current | |
| CEO | Simon Glerup Pedersen | ||
| Board | Simon Glerup Pedersen | Current | |
| Board | Stefan Emanuel Luzi | Current | |
| Board | Robert Andrew Donald Scott | Current | |
| Board | Emmanuelle Coutanceau | Current | |
| Board | Eva-Lotta Coulter | Current | |
| Board | Ivan Burkov | Current | |
| Board | Camilla Gustafsen | ||
| Board | Simon Glerup Pedersen | ||
| Board | Peder Søndergaard Madsen | ||
| Board | Emmanuelle Coutanceau | ||
| Board | Peter Hans Andreas Seeberger | ||
| Board | Fiona MacLaughlin | ||
| Board | Roel Bulthuis | ||
| Owner (10%) | MP Healthcare Venture Management, Inc, | Current | |
| Owner (20%) | Novo Holdings A/S | Current | |
| Owner (10%) | Danmarks Eksport- og Investeringsfond | Current | |
| Owner (20%) | Coöperatieve Gilde Healthcare IV U.A. | Current | |
| Owner (20%) | INKEF Holding Coöperatief U.A. | Current | |
| Owner (25%) | Camilla Gustafsen Consulting ApS | ||
| Owner (25%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (25%) | Simon Glerup Consulting ApS | ||
| Owner (25%) | Seeberger Science GmbH | ||
| Owner (20%) | Camilla Gustafsen Consulting ApS | ||
| Owner (20%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (20%) | Simon Glerup Consulting ApS | ||
| Owner (20%) | Seeberger Science GmbH | ||
| Owner (25%) | Novo Holdings A/S | ||
| Owner (5%) | Camilla Gustafsen Consulting ApS | ||
| Owner (5%) | Peder Søndergaard Madsen Consulting ApS | ||
| Owner (5%) | Simon Glerup Consulting ApS | ||
| Owner (5%) | Seeberger Science GmbH | ||
| Owner (5%) | High-Tech Gründerfonds III GmbH & Co. KG | ||
| Owner (15%) | Coöperatieve Gilde Healthcare IV U.A. | ||
| Owner (15%) | Stichting Depositary INKEF Investment Fund | ||
| Owner (20%) | Coöperatieve Gilde Healthcare IV U.A. | ||
| Owner (20%) | Stichting Depositary INKEF Investment Fund | ||
| Owner (25%) | Coöperatieve Gilde Healthcare IV U.A. | ||
| Owner (25%) | Novo Holdings A/S | ||
| Owner (25%) | Coöperatieve Gilde Healthcare IV U.A. | ||
| Owner (25%) | Stichting Depositary INKEF Investment Fund | ||
| Owner (20%) | Stichting Depositary INKEF Investment Fund | ||
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Auditor | BDO Holding VII, statsautoriseret revisionsaktieselskab | ||
| Founder | Camilla Gustafsen Consulting ApS | Current | |
| Founder | Peder Søndergaard Madsen Consulting ApS | Current | |
| Founder | Simon Glerup Consulting ApS | Current |
The CEOs' other companies
Simon Glerup Pedersen – 3 other companies
- ENDOGEN ApS Active
- Muna Therapeutics ApS Active
- Simon Glerup Consulting ApS Active
Address history (4 moves)
| c/o Symbion Fuglebakken, Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N | |
| Tuborgvej 5, 2900 Hellerup | |
| c/o Bio Innovation Institute, Ole Maaløes Vej 3, 2200 København N | |
| Solsikkevej 8, 8240 Risskov |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Koblano Therapeutics ApS Frederiksberg
- Eygo Bio ApS Frederiksberg
- LumenAR ApS Frederiksberg
- IDTA ApS Frederiksberg
- Valicentra ApS Frederiksberg
- Silvics ApS Frederiksberg
- InLife Research ApS Frederiksberg
- NordicRWE Denmark ApS Frederiksberg C
- CaMaRa ApS Frederiksberg
- Hvidberg Compliance Management Aps Frederiksberg
- Vibraint ApS Frederiksberg
- Augustine Therapeutics Denmark ApS Frederiksberg
Questions and answers about Draupnir Bio ApS
Has Draupnir Bio ApS gone bankrupt?
No, Draupnir Bio ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Draupnir Bio ApS?
Our model estimates a bankruptcy risk of 4.5% over the next 12 months (high risk), which is 3.2 times the average for Danish companies.
Who is the CEO of Draupnir Bio ApS?
Andrew Thomas Hotchkiss is the CEO of Draupnir Bio ApS.
Who is the auditor of Draupnir Bio ApS?
Draupnir Bio ApS most recently used DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was Draupnir Bio ApS founded?
Draupnir Bio ApS was founded on 4 April 2017.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.